• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.

作者信息

Cantini Fabrizio, Benucci Maurizio

机构信息

Department of Rheumatology, Azienda USL Toscana Centro, Hospital of Prato, Prato, Italy

Rheumatology Clinic, Azienda USL Toscana Centro, Nuovo S Giovanni di Dio Hospital, Florence, Italy.

出版信息

Ann Rheum Dis. 2020 Feb;79(2):e13. doi: 10.1136/annrheumdis-2018-214757. Epub 2018 Nov 28.

DOI:10.1136/annrheumdis-2018-214757
PMID:30487149
Abstract
摘要

相似文献

1
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.强制的、成本驱动的从原研药依那西普转换为其生物类似药SB4：对非医学转换可能产生的影响。
Ann Rheum Dis. 2020 Feb;79(2):e13. doi: 10.1136/annrheumdis-2018-214757. Epub 2018 Nov 28.
2
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB: possible fallout on non-medical switching' by Cantini and Benucci.对坎蒂尼和贝努奇所著《强制、成本驱动下从原研依那西普转换为其生物类似药SB：非医学转换可能产生的影响》的回应
Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20.
3
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.是否切换：全国强制性从原研药切换至生物类似药依那西普的指南结果。DANBIO 登记处 2061 例炎性关节炎患者的 1 年治疗结果。
Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5.
4
Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.开放性、非强制性由依那西普原研药转换为生物类似药 SB4：一项对照队列研究的 6 个月结果。
Arthritis Rheumatol. 2018 Sep;70(9):1408-1418. doi: 10.1002/art.40516. Epub 2018 Aug 6.
5
Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.英国类风湿关节炎患者从原研药转换为生物类似药依那西普的非医学相关费用。
J Med Econ. 2019 Nov;22(11):1162-1170. doi: 10.1080/13696998.2019.1652183. Epub 2019 Sep 9.
6
Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.从原研药到生物类似药依那西普的强制性非医学转换是否会导致炎症性关节炎患者的医疗保健使用和成本增加？一项丹麦基于登记的研究。
RMD Open. 2019 Aug 12;5(2):e001016. doi: 10.1136/rmdopen-2019-001016. eCollection 2019.
7
Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).从原研药到生物类似药依那西普（SB4）转换过程中的接受率和社会学因素。
Semin Arthritis Rheum. 2019 Apr;48(5):927-932. doi: 10.1016/j.semarthrit.2018.07.005. Epub 2018 Jul 20.
8
Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.依那西普生物类似药转换治疗与继续使用依那西普治疗对病情稳定的类风湿关节炎患者的疗效：一项前瞻性多国观察性研究。
Adv Ther. 2022 Nov;39(11):5259-5273. doi: 10.1007/s12325-022-02303-1. Epub 2022 Sep 22.
9
Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.依那西普生物类似药 SB4 维持银屑病关节炎患者低疾病活动度的疗效：一项开放性标签、为期一年的研究。
J Dermatolog Treat. 2020 Nov;31(7):687-691. doi: 10.1080/09546634.2019.1606886. Epub 2019 May 1.
10
Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration.比较依那西普生物类似药SB4与原研依那西普的免疫原性：另一项考量
Ann Rheum Dis. 2016 Jul;75(7):e37. doi: 10.1136/annrheumdis-2016-209502. Epub 2016 Mar 31.

引用本文的文献

1
Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.在炎症性关节炎患者队列中，从依那西普原研药转为依那西普生物类似药的单一转换的疗效和安全性。
Sci Rep. 2020 Sep 30;10(1):16178. doi: 10.1038/s41598-020-73183-0.
2
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?从原研药非医学性转换为生物类似药：无安慰剂效应能否解释风湿病学和胃肠病学中的治疗失败及不良事件？
Rheumatol Ther. 2020 Mar;7(1):35-64. doi: 10.1007/s40744-019-00190-7. Epub 2020 Jan 16.
3
Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.
从原研药到生物类似药依那西普的强制性非医学转换是否会导致炎症性关节炎患者的医疗保健使用和成本增加？一项丹麦基于登记的研究。
RMD Open. 2019 Aug 12;5(2):e001016. doi: 10.1136/rmdopen-2019-001016. eCollection 2019.